Gee AP - Search Results

1

[Impact of regulations on translational research in cell and gene therapy: the American experience].

Rousseau RF, Gee AP. Rousseau RF, et al. Among authors: gee ap. Bull Cancer. 2004 Mar;91(3):239-47. Bull Cancer. 2004. PMID: 15171048 French.

2

Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility.

Grilley BJ, Gee AP. Grilley BJ, et al. Among authors: gee ap. Cytotherapy. 2003;5(3):197-207. doi: 10.1080/14653240310001271. Cytotherapy. 2003. PMID: 12850787 Review.

3

A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products.

Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R. Gee AP, et al. Cytotherapy. 2008;10(4):427-35. doi: 10.1080/14653240802075476. Cytotherapy. 2008. PMID: 18574775 Free PMC article.

4

Manufacturing genetically modified T cells for clinical trials.

Gee AP. Gee AP. Cancer Gene Ther. 2015 Mar;22(2):67-71. doi: 10.1038/cgt.2014.71. Epub 2015 Jan 30. Cancer Gene Ther. 2015. PMID: 25633481 Review.

5

Product release assays.

Gee AP. Gee AP. Cytotherapy. 1999;1(6):485-91. doi: 10.1080/0032472031000141309. Cytotherapy. 1999. PMID: 20426549 No abstract available.

6

What a cell-processing laboratory can and can't do for cellular therapy.

Gee AP. Gee AP. Cytotherapy. 2002;4(5):447-8. doi: 10.1080/146532402320776143. Cytotherapy. 2002. PMID: 12473221 No abstract available.

7

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Heslop HE, et al. Among authors: gee ap. Cytotherapy. 2002;4(5):433-4. doi: 10.1080/146532402320776071. Cytotherapy. 2002. PMID: 12473214 Review. No abstract available.

8

Cell sorting for therapeutic applications - points to consider.

Gee AP, Durett AG. Gee AP, et al. Cytotherapy. 2002;4(1):91-2. doi: 10.1080/146532402317251608. Cytotherapy. 2002. PMID: 11953049 No abstract available.

9

Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.

Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Heslop H, et al. Hum Gene Ther. 2000 Jul 1;11(10):1465-75. doi: 10.1089/10430340050057530. Hum Gene Ther. 2000. PMID: 10910143 Clinical Trial. No abstract available.

10

Mesenchymal stem-cell therapy in a regulated environment.

Gee A. Gee A. Cytotherapy. 2001;3(5):397-8. doi: 10.1080/146532401753277391. Cytotherapy. 2001. PMID: 11953020 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results